The expression profile of Cetuximab resistance in head-and-neck squamous cell carcinoma cells.
Ontology highlight
ABSTRACT: Cetuximab (Erbitux) is an antibody drug against EGFR and commonly used in late stage HNSCC and metastatic colorectal cancer. The oncogenic mutation of certain genes are known to drive Cetuximab resistance such as K-RAS or b-RAF mutation. The aberrant activation of signaling pathways in the presence of Cetuximab treatment to overcome cellular stress contribute to acquired resistance to Cetuximab as well. To better understand the mechanisms and molecular patterns of Cetuximab resistant cells, the Cetuximab resistant cells are trained for examining the gene expression profile. The gene expression array is used for identify the molecular signature governing the Cetuximab resitance.
ORGANISM(S): Homo sapiens
PROVIDER: GSE63916 | GEO | 2017/03/02
SECONDARY ACCESSION(S): PRJNA269491
REPOSITORIES: GEO
ACCESS DATA